Novo Nordisk scored a major win in its wide-ranging legal fight to keep compounders from making copies of its obesity drug semaglutide. A federal district court in Texas on Thursday denied a request for a …
In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk for falls, and combined use with GLP-1 RAs nearly tripled the risk. Medscape Medical News
In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published April 23 in the American Journal of Health-System Pharmacy, reviewed the IQVIA National Sales Perspectives database, which tracks medication purchases by hospitals, clinics, retail pharmacies, mail-order … Read more
Nature Reviews Drug Discovery, Published online: 25 April 2025; doi:10.1038/s41573-025-01183-8 GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based medicines, focusing on novel GLP-1 receptor agonists and GLP-1-based multi-agonists. Considerations and challenges in the development of GLP-1-based therapies and potential future indications are … Read more
While some Americans might feel doubtful about prescriptions, others are doing all they can to acquire GLP-1 drugs. Carly Johnson of Momentum Worldwide says the results of a new survey show just how popular they are. If you spend even a little bit of time online, you’ve probably seen the social discourse around prescription medications … Read more
BLOCKBUSTER ‘Ozempic-style’ fat jabs could increase the risk of depression and suicidal thoughts, experts have warned. The injections have allegedly helped celebs like Sun columnist Jeremy Clarkson, Sharon Osbourne and ex-Prime Minister Boris Johnson to shed some pounds. GettyScientists think fat jabs upset dopamine levels in the brain and raise the risk of depression, anxiety, and suicidal thoughts[/caption] Since … Read more
Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge eating disorder? And how can clinicians protect patients from risk? Medscape Medical News
BACKGROUND Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. PURPOSE In these meta-analyses, including new data from the Semaglutide cardiOvascular oUtcomes triaL (SOUL) (oral semaglutide) and Evaluate Renal Function with Semaglutide … Read more
A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD. Medscape Medical News
